Chembio Diagnostics (NASDAQ:CEMI – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.08), MarketWatch Earnings reports. Chembio Diagnostics had a negative net margin of 70.90% and a negative return on equity of 89.24%. During the same quarter in the previous year, the company posted ($0.22) EPS.
CEMI stock traded down $0.11 on Friday, hitting $0.56. 270,626 shares of the company were exchanged, compared to its average volume of 194,877. Chembio Diagnostics has a twelve month low of $0.53 and a twelve month high of $7.34. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.59 and a quick ratio of 2.74. The business’s fifty day moving average is $0.75 and its two-hundred day moving average is $1.25. The stock has a market capitalization of $16.86 million, a price-to-earnings ratio of -0.38 and a beta of 1.73.
Several equities analysts recently issued reports on CEMI shares. Zacks Investment Research downgraded shares of Chembio Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 9th. Colliers Securities reissued a “neutral” rating on shares of Chembio Diagnostics in a research note on Tuesday, March 22nd. Finally, StockNews.com assumed coverage on shares of Chembio Diagnostics in a research note on Thursday. They set a “sell” rating on the stock.
About Chembio Diagnostics (Get Rating)
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases.
- Get a free copy of the StockNews.com research report on Chembio Diagnostics (CEMI)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.